A network of dopaminergic gene variations implicated as risk factors for schizophrenia.

We evaluated the hypothesis that dopaminergic polymorphisms are risk factors for schizophrenia (SZ). In stage I, we screened 18 dopamine-related genes in two independent US Caucasian samples: 150 trios and 328 cases/501 controls. The most promising associations were detected with SLC6A3 (alias DAT), DRD3, COMT and SLC18A2 (alias VMAT2). In stage II, we comprehensively evaluated these four genes by genotyping 68 SNPs in all 478 cases and 501 controls from stage I. Fifteen (23.1%) significant associations were found (p < or = 0.05). We sought epistasis between pairs of SNPs providing evidence of a main effect and observed 17 significant interactions (169 tests); 41.2% of significant interactions involved rs3756450 (5' near promoter) or rs464049 (intron 4) at SLC6A3. In stage III, we confirmed our findings by genotyping 65 SNPs among 659 Bulgarian trios. Both SLC6A3 variants implicated in the US interactions were overtransmitted in this cohort (rs3756450, p = 0.035; rs464049, p = 0.011). Joint analyses from stages II and III identified associations at all four genes (p(joint) < 0.05). We tested 29 putative interactions from stage II and detected replication between seven locus pairs (p < or = 0.05). Simulations suggested our stage II and stage III interaction results were unlikely to have occurred by chance (p = 0.008 and 0.001, respectively). In stage IV we evaluated rs464049 and rs3756450 for functional effects and found significant allele-specific differences at rs3756450 using electrophoretic mobility shift assays and dual-luciferase promoter assays. Our data suggest that a network of dopaminergic polymorphisms increase risk for SZ.

[1]  M. Talkowski,et al.  Dopamine genes and schizophrenia: case closed or evidence pending? , 2007, Schizophrenia bulletin.

[2]  M. Owen,et al.  Is COMT a susceptibility gene for schizophrenia? , 2007, Schizophrenia bulletin.

[3]  M. Loza,et al.  Extensive linkage disequilibrium mapping at HTR2A and DRD3 for schizophrenia susceptibility genes in the Galician population , 2007, Schizophrenia Research.

[4]  K. Shokat,et al.  Human Catechol-O-Methyltransferase Haplotypes Modulate Protein Expression by Altering mRNA Secondary Structure , 2006, Science.

[5]  B. Devlin,et al.  Novel, Replicated Associations Between Dopamine D3 Receptor Gene Polymorphisms and Schizophrenia in Two Independent Samples , 2006, Biological Psychiatry.

[6]  M. Knapp,et al.  Family-based study of markers at the 5′-flanking region of the human dopamine transporter gene reveals potential association with schizophrenic psychoses , 2006, European Archives of Psychiatry and Clinical Neuroscience.

[7]  G. Torres,et al.  The dopamine transporter proteome , 2006, Journal of neurochemistry.

[8]  T. Sotnikova,et al.  Molecular biology, pharmacology and functional role of the plasma membrane dopamine transporter. , 2006, CNS & neurological disorders drug targets.

[9]  G. Abecasis,et al.  Joint analysis is more efficient than replication-based analysis for two-stage genome-wide association studies , 2006, Nature Genetics.

[10]  S. Macgregor,et al.  GAIA: An easy-to-use web-based application for interaction analysis of case-control data , 2006, BMC Medical Genetics.

[11]  R. Huganir,et al.  Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. , 2005, American journal of human genetics.

[12]  Nicolas Peyret,et al.  The SNPlex genotyping system: a flexible and scalable platform for SNP genotyping. , 2005, Journal of biomolecular techniques : JBT.

[13]  B. Devlin,et al.  Catechol-O-methyltransferase haplotypes are associated with psychosis in Alzheimer disease , 2005, Molecular Psychiatry.

[14]  G. Kirov,et al.  No association between schizophrenia and polymorphisms in COMT in two large samples. , 2005, The American journal of psychiatry.

[15]  C. Carlson,et al.  Dopamine transporter (SLC6A3) 5′ region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease , 2005, Pharmacogenetics & Genomics.

[16]  M. Munafo,et al.  Lack of association of the COMT (Val158/108 Met) gene and schizophrenia: a meta-analysis of case–control studies , 2005, Molecular Psychiatry.

[17]  K. Gunderson,et al.  High-throughput SNP genotyping on universal bead arrays. , 2005, Mutation research.

[18]  M. R. Sargolzaee,et al.  Association analysis of the dopamine transporter (DAT1)‐67A/T polymorphism in bipolar disorder , 2005, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[19]  Alessandro Rinaldo,et al.  Characterization of multilocus linkage disequilibrium , 2005, Genetic epidemiology.

[20]  S. Faraone,et al.  Meta-analysis shows schizophrenia is not associated with the 40-base-pair repeat polymorphism of the dopamine transporter gene , 2005, Schizophrenia Research.

[21]  Lin He,et al.  Catechol-O-methyltransferase gene Val/Met functional polymorphism and risk of schizophrenia: A large-scale association study plus meta-analysis , 2005, Biological Psychiatry.

[22]  D. Kupfer,et al.  Serotonin gene polymorphisms and bipolar I disorder: Focus on the serotonin transporter , 2005, Annals of medicine.

[23]  H. Najmabadi,et al.  Association of the dopamine transporter gene (DAT1) core promoter polymorphism −67T variant with schizophrenia , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[24]  J Tuomilehto,et al.  Cost-effective analysis of candidate genes using htSNPs: a staged approach , 2004, Genes and Immunity.

[25]  Ivan Nikolov,et al.  Strong evidence for association between the dystrobrevin binding protein 1 gene (DTNBP1) and schizophrenia in 488 parent-offspring trios from Bulgaria , 2004, Biological Psychiatry.

[26]  Heather J Cordell,et al.  Case/pseudocontrol analysis in genetic association studies: A unified framework for detection of genotype and haplotype associations, gene‐gene and gene‐environment interactions, and parent‐of‐origin effects , 2004, Genetic epidemiology.

[27]  R. Kaiser,et al.  Meta-analysis of the dopamine D3 receptor gene (DRD3) Ser9Gly variant and schizophrenia , 2004, Psychiatric genetics.

[28]  R. Weinshilboum,et al.  Human catechol O-methyltransferase genetic variation: gene resequencing and functional characterization of variant allozymes , 2004, Molecular Psychiatry.

[29]  Toshihiro Tanaka.  The International HapMap Project , 2003, Nature.

[30]  R. Elston,et al.  Optimal two‐stage genotyping in population‐based association studies , 2003, Genetic epidemiology.

[31]  F. Dudbridge.  Pedigree disequilibrium tests for multilocus haplotypes , 2003, Genetic epidemiology.

[32]  Michael C O'Donovan,et al.  A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. , 2003, American journal of human genetics.

[33]  Leena Peltonen,et al.  Genome scan meta-analysis of schizophrenia and bipolar disorder, part II: Schizophrenia. , 2003, American journal of human genetics.

[34]  S. Faraone,et al.  Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case-control and family-based studies. , 2003, The American journal of psychiatry.

[35]  G. Sedvall,et al.  Dopamine D3 receptor gene Ser9Gly variant and schizophrenia: association study and meta-analysis , 2003, Psychiatric genetics.

[36]  H Zhao,et al.  Group sequential methods and sample size savings in biomarker-disease association studies. , 2003, Genetics.

[37]  J. Beckmann,et al.  A highly significant association between a COMT haplotype and schizophrenia. , 2002, American journal of human genetics.

[38]  Paul Schliekelman,et al.  Multiplex relative risk and estimation of the number of loci underlying an inherited disease. , 2002, American journal of human genetics.

[39]  A. Zapata,et al.  D3 receptor ligands modulate extracellular dopamine clearance in the nucleus accumbens , 2002, Journal of neurochemistry.

[40]  G. Kirov,et al.  Dopamine transporter gene (DAT1) VNTR polymorphism in major psychiatric disorders: family‐based association study in the Bulgarian population , 2002, Acta psychiatrica Scandinavica.

[41]  D. Clayton,et al.  A unified stepwise regression procedure for evaluating the relative effects of polymorphisms within a gene using case/control or family data: application to HLA in type 1 diabetes. , 2002, American journal of human genetics.

[42]  M. Bannon,et al.  The human dopamine transporter gene: gene organization, transcriptional regulation, and potential involvement in neuropsychiatric disorders , 2001, European Neuropsychopharmacology.

[43]  J. Ioannidis,et al.  Replication validity of genetic association studies , 2001, Nature Genetics.

[44]  N. Zahniser,et al.  Chronic and acute regulation of Na+/Cl- -dependent neurotransmitter transporters: drugs, substrates, presynaptic receptors, and signaling systems. , 2001, Pharmacology & therapeutics.

[45]  S. Nanko,et al.  Exon/intron boundaries, novel polymorphisms, and association analysis with schizophrenia of the human synaptic vesicle monoamine transporter (SVMT) gene , 2001, Molecular Psychiatry.

[46]  David A Lewis,et al.  Catching Up on Schizophrenia Natural History and Neurobiology , 2000, Neuron.

[47]  R. Murray,et al.  Family-based linkage disequilibrium mapping using SNP marker haplotypes: application to a potential locus for schizophrenia at chromosome 22q11 , 2000, Molecular Psychiatry.

[48]  K. Roeder,et al.  The power of genomic control. , 2000, American journal of human genetics.

[49]  Xin Xu,et al.  Implementing a unified approach to family‐based tests of association , 2000, Genetic epidemiology.

[50]  K. Roeder,et al.  Genomic Control for Association Studies , 1999, Biometrics.

[51]  M. Laruelle,et al.  Increased dopamine transmission in schizophrenia: relationship to illness phases , 1999, Biological Psychiatry.

[52]  M. Laruelle,et al.  Dopamine as the wind of the psychotic fire: new evidence from brain imaging studies , 1999, Journal of psychopharmacology.

[53]  J R O'Connell,et al.  PedCheck: a program for identification of genotype incompatibilities in linkage analysis. , 1998, American journal of human genetics.

[54]  J. Krystal,et al.  Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. , 1998, The American journal of psychiatry.

[55]  C. Easton,et al.  Test-retest reliability of the alcohol and drug use disorder sections of the schedules for clinical assessment in neuropsychiatry (SCAN). , 1997, Drug and alcohol dependence.

[56]  L. Petrangeli,et al.  Schedules for Clinical Assessment in Neuropsychiatry , 1997, Epidemiologia e Psichiatria Sociale.

[57]  A. Malhotra,et al.  Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[58]  J. Krystal,et al.  Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[59]  A. Cesura,et al.  The role of monoamine oxidase and catechol O-methyltransferase in dopaminergic neurotransmission. , 1995, Journal of neural transmission. Supplementum.

[60]  J. Nurnberger,et al.  Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative. , 1994, Archives of general psychiatry.

[61]  M. Martres,et al.  Pharmacology of human dopamine D3 receptor expressed in a mammalian cell line: comparison with D2 receptor. , 1992, European journal of pharmacology.

[62]  F. Vogel,et al.  Schizophrenia genesis: The origins of madness , 1991 .

[63]  N. Andrews,et al.  A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. , 1991, Nucleic acids research.

[64]  Bruno Giros,et al.  Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics , 1990, Nature.

[65]  T. Brugha,et al.  SCAN. Schedules for Clinical Assessment in Neuropsychiatry. , 1990, Archives of general psychiatry.

[66]  N. Risch,et al.  Genetic linkage and complex diseases, with special reference to psychiatric disorders , 1990, Genetic epidemiology.

[67]  L. Siever,et al.  L-dopa challenge and relapse in schizophrenia. , 1987, The American journal of psychiatry.

[68]  B. Angrist,et al.  CNS stimulants as tools in the study of schizophrenia , 1984, Trends in Neurosciences.

[69]  J. Lieberman,et al.  Methylphenidate challenge as a predictor of relapse in schizophrenia. , 1984, The American journal of psychiatry.

[70]  P. Seeman,et al.  Antipsychotic drug doses and neuroleptic/dopamine receptors , 1976, Nature.

[71]  S H Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs , 1976, Science.

[72]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.